Using a lung cancer model, they demonstrated improved induction of anti-tumor immunity and tumor infiltration by CD8 T cells following treatment with their IFN-β-expressing vaccinia variant compared to the control virus [122]. The gene discussed is CD8A; the disease is neoplasm.